Yazarlar |
Hakan Erdem
Gülhane Askeri Tıp Akademisi, Türkiye |
Ayşegül Ulu Kılıç
Erciyes Üniversitesi, Türkiye |
Selim Kılıç
Gülhane Askeri Tıp Akademisi, Türkiye |
Prof. Dr. Mustafa Kasım KARAHOCAGİL
Yüzüncü Yıl Üniversitesi, Türkiye |
Shehata Ghaydaa
|
Necla Eren Tülek
|
Funda Yetkin
İnönü Üniversitesi, Türkiye |
Mustafa Kemal Çelen
Dicle Üniversitesi, Türkiye |
Nurgül Ceran
|
Hanefi Cem Gül
|
Gürkan Mert
|
Suda Tekin Koruk
|
Murat Dizbay
Gazi Üniversitesi, Türkiye |
İnal A Yşe Seza
|
Saygın Nayman-Alpat
|
Mile Bosilkovski
|
Dilara İnan
Akdeniz Üniversitesi, Türkiye |
Neşe Saltoğlu
İstanbul Üniversitesi, Türkiye |
Laila Abdel Baky
|
Marıa Teresa Adeva Bartolome
|
Bahadır Ceylan
İstanbul Medipol Üniversitesi, Türkiye |
Suzan Saçar
Çanakkale Onsekiz Mart Üniversitesi, Türkiye |
Vedat Turhan
Gülhane Askeri Tıp Akademisi, Türkiye |
Emel Yılmaz
Uludağ Üniversitesi, Türkiye |
Nazif Elaldı
Cumhuriyet Üniversitesi, Türkiye |
Zeliha Koçak Tufan
Yıldırım Beyazıt Üniversitesi, Türkiye |
Kenan Uğurlu
|
Başak Dokuzoğuz
|
Hava Yılmaz
Ondokuz Mayıs Üniversitesi, Türkiye |
Sibel Gündeş
Kocaeli Üniversitesi, Türkiye |
Hatice Rahmet Güner
Yıldırım Beyazıt Üniversitesi, Türkiye |
Nail Ozgüneş
|
Asım Ulcay
|
Serhat Ünal
Hacettepe Üniversitesi, Türkiye |
Saim Dayan
Dicle Üniversitesi, Türkiye |
Levent Görenek
Gülhane Askeri Tıp Akademisi, Türkiye |
Ahmet Karakaş
|
Yeşim Taşova
Çukurova Üniversitesi, Türkiye |
Gaye Usluer
Eskişehir Osmangazi Üniversitesi, Türkiye |
Yaşar Bayındır
İnönü Üniversitesi, Türkiye |
Behice Kurtaran
Çukurova Üniversitesi, Türkiye |
Osman Hakan Leblebicioğlu
Ondokuz Mayıs Üniversitesi, Türkiye |
Özet |
No data on whether brucellar meningitis or meningoencephalitis can be treated with oral antibiotics or whether an intravenous extended-spectrum cephalosporin, namely, ceftriaxone, which does not accumulate in phagocytes, should be added to the regimen exist in the literature. The aim of a study conducted in Istanbul, Turkey, was to compare the efficacy and tolerability of ceftriaxone-based antibiotic treatment regimens with those of an oral treatment protocol in patients with these conditions. This retrospective study enrolled 215 adult patients in 28 health care institutions from four different countries. The first protocol (P1) comprised ceftriaxone, rifampin, and doxycycline. The second protocol (P2) consisted of trimethoprim-sulfamethoxazole, rifampin, and doxycycline. In the third protocol (P3), the patients started with P1 and transferred to P2 when ceftriaxone was stopped. The treatment period was shorter with the regimens which included ceftriaxone (4.40 +/- 2.47 months in P1, 6.52 +/- 4.15 months in P2, and 5.18 +/- 2.27 months in P3) (P = 0.002). In seven patients, therapy was modified due to antibiotic side effects. When these cases were excluded, therapeutic failure did not differ significantly between ceftriaxone-based regimens (n = 5/166, 3.0%) and the oral therapy (n = 4/42, 9.5%) (P = 0.084). The efficacy of the ceftriaxone-based regimens was found to be better (n = 6/166 [3.6%] versus n = 6/42 [14.3%]; P = 0.017) when a composite negative outcome (CNO; relapse plus therapeutic failure) was considered. Accordingly, CNO was greatest in P2 (14.3%, n = 6/42) compared to P1 (2.6%, n = 3/ 117) and P3 (6.1%, n = 3/ 49) (P = 0.020). Seemingly, ceftriaxone-based regimens are more successful and require shorter therapy than the oral treatment protocol. |
Anahtar Kelimeler |
Makale Türü | Özgün Makale |
Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
Dergi Adı | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY |
Dergi ISSN | 0066-4804 |
Dergi Tarandığı Indeksler | SSCI |
Makale Dili | İngilizce |
Basım Tarihi | 03-2012 |
Cilt No | 56 |
Sayı | 3 |
Sayfalar | 1523 / 1528 |
Doi Numarası | 10.1128/AAC.05974-11 |
Makale Linki | http://aac.asm.org/cgi/doi/10.1128/AAC.05974-11 |